Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non‐erosive reflux disease – a double‐blind, placebo‐controlled study

Aliment Pharmacol Ther 2011; 33: 323–332 Summary Background Proton pump inhibitors (PPIs) are less effective in non‐erosive reflux disease (NERD) patients than in reflux oesophagitis patients. Whether the addition of prokinetics to PPIs improves NERD patients’ symptoms remains unknown. Aim To evaluate the efficacy of mosapride in NERD patients when used with PPI. Methods A total of 200 NERD patients were randomised to one of two arms: omeprazole (10 mg once daily) plus mosapride citrate (5 mg three times a day) (treatment arm) and omeprazole plus placebo (placebo arm). The primary endpoint was the rate of responders [visual analogue scale (VAS) was zero or